PDF(Pubmed)
Abstract：
UNASSIGNED: In coronavirus disease 2019 (COVID-19), particularly in older people, dysregulated immune response and aberrant repair can result in varied severity secondary pulmonary fibrosis (PF). By detecting some indicators, the occurrence and prognosis of fibrosis can be measured, providing directions for COVID-19 treatment.
UNASSIGNED: The research study lasted for 3 months and involved 88 COVID-19 patients. According to the chest radiological examination, 47 (53.41%) individuals were found to have no PF, while 41 (46.59%) showed PF. Clinical data such as inflammation markers, imaging findings, blood gas analysis, and hospital stay length were collected.
UNASSIGNED: With area under the curve values of 0.7413, 0.7741, and 0.7048, respectively, and the study of the receiver operating characteristic curve demonstrated that mucin 1 (MUC1), carcinoembryonic antigen (CEA), and CXC chemokine receptor 10 (CXCL10) could diagnose the presence of COVID-19 PF. To evaluate the possibility of PF following severe acute respiratory syndrome coronavirus-2 infection, we established particular values for MUC1, CEA, and CXCL10 (1.296 ng/ml, 4.315 ng/ml, and 32.77 ng/ml, respectively). The survival curve for hospital days indicated that the length of hospital stays positively correlated with these three factors (P < 0.01). Transforming growth factor-beta did not correlate significantly with the severity of COVID-19 or PF.
UNASSIGNED: The results of this study suggested that the MUC1, CEA, and CXCL10 can be employed to explore the severity of secondary PF in COVID-19.
UNASSIGNED: The research study lasted for 3 months and involved 88 COVID-19 patients. According to the chest radiological examination, 47 (53.41%) individuals were found to have no PF, while 41 (46.59%) showed PF. Clinical data such as inflammation markers, imaging findings, blood gas analysis, and hospital stay length were collected.
UNASSIGNED: With area under the curve values of 0.7413, 0.7741, and 0.7048, respectively, and the study of the receiver operating characteristic curve demonstrated that mucin 1 (MUC1), carcinoembryonic antigen (CEA), and CXC chemokine receptor 10 (CXCL10) could diagnose the presence of COVID-19 PF. To evaluate the possibility of PF following severe acute respiratory syndrome coronavirus-2 infection, we established particular values for MUC1, CEA, and CXCL10 (1.296 ng/ml, 4.315 ng/ml, and 32.77 ng/ml, respectively). The survival curve for hospital days indicated that the length of hospital stays positively correlated with these three factors (P < 0.01). Transforming growth factor-beta did not correlate significantly with the severity of COVID-19 or PF.
UNASSIGNED: The results of this study suggested that the MUC1, CEA, and CXCL10 can be employed to explore the severity of secondary PF in COVID-19.
摘要：
■在2019年冠状病毒病（COVID-19）中，尤其是老年人，失调的免疫反应和异常的修复可导致不同严重程度的继发性肺纤维化（PF）。通过检测一些指标，可以测量纤维化的发生和预后，为COVID-19治疗提供指导。
■这项研究持续了3个月，涉及88名COVID-19患者。根据胸部放射学检查，47人(53.41%)没有PF，41例（46.59%）显示PF。临床数据，如炎症标志物，影像学发现，血气分析,并收集住院时间。
■曲线下面积值分别为0.7413、0.7741和0.7048，对受试者工作特性曲线的研究表明，粘蛋白1(MUC1)，癌胚抗原(CEA),CXC趋化因子受体10（CXCL10）可以诊断COVID-19PF的存在。评估严重急性呼吸综合征冠状病毒-2感染后PF的可能性，我们建立了MUC1、CEA、和CXCL10(1.296ng/ml，4.315ng/ml,和32.77ng/ml，分别)。住院天数的生存曲线表明住院时间与这三个因素呈正相关（P<0.01）。转化生长因子-β与COVID-19或PF的严重程度没有显着相关。
■这项研究的结果表明，MUC1，CEA，和CXCL10可用于探索COVID-19继发性PF的严重程度。
■这项研究持续了3个月，涉及88名COVID-19患者。根据胸部放射学检查，47人(53.41%)没有PF，41例（46.59%）显示PF。临床数据，如炎症标志物，影像学发现，血气分析,并收集住院时间。
■曲线下面积值分别为0.7413、0.7741和0.7048，对受试者工作特性曲线的研究表明，粘蛋白1(MUC1)，癌胚抗原(CEA),CXC趋化因子受体10（CXCL10）可以诊断COVID-19PF的存在。评估严重急性呼吸综合征冠状病毒-2感染后PF的可能性，我们建立了MUC1、CEA、和CXCL10(1.296ng/ml，4.315ng/ml,和32.77ng/ml，分别)。住院天数的生存曲线表明住院时间与这三个因素呈正相关（P<0.01）。转化生长因子-β与COVID-19或PF的严重程度没有显着相关。
■这项研究的结果表明，MUC1，CEA，和CXCL10可用于探索COVID-19继发性PF的严重程度。
